Minerva Neurosciences Is Maintained at Neutral by HC Wainwright & Co.

Investing.com – U.S. stocks were mixed after the close on Tuesday, as gains in the Consumer Services, Industrials and Healthcare sectors led shares higher while losses in the Basic Materials, Utilities and Telecoms sectors led shares lower.

At the close in NYSE, the Dow Jones Industrial Average added 0.47% to hit a new all time high, while the S&P 500 index climbed 0.00%, and the NASDAQ Composite index fell 0.16%.

The best performers of the session on the Dow Jones Industrial Average were 3M Company (NYSE:MMM), which rose 7.66% or 11.86 points to trade at 166.64 at the close. Meanwhile, Coca-Cola Co (NYSE:KO) added 4.06% or 2.78 points to end at 71.22 and Salesforce Inc (NYSE:CRM) was up 3.59% or 9.13 points to 263.41 in late trade.

The worst performers of the session were JPMorgan Chase & Co (NYSE:JPM), which fell 1.74% or 5.27 points to trade at 297.09 at the close. Verizon Communications Inc (NYSE:VZ) declined 1.24% or 0.51 points to end at 40.30 and Caterpillar Inc (NYSE:CAT) was down 1.23% or 6.53 points to 524.65.

The top performers on the S&P 500 were General Motors Company (NYSE:GM) which rose 14.82% to 66.60, Halliburton Company (NYSE:HAL) which was up 11.52% to settle at 25.23 and Warner Bros Discovery Inc (NASDAQ:WBD) which gained 10.97% to close at 20.33.

The worst performers were Newmont Goldcorp Corp (NYSE:NEM) which was down 9.05% to 86.31 in late trade, Albemarle Corp (NYSE:ALB) which lost 5.00% to settle at 91.34 and Vistra Energy Corp (NYSE:VST) which was down 3.97% to 186.52 at the close.

The top performers on the NASDAQ Composite were Beyond Meat Inc (NASDAQ:BYND) which rose 146.27% to 3.62, Minerva Neurosciences Inc (NASDAQ:NERV) which was up 140.98% to settle at 6.41 and rYojbaba Co Ltd (NASDAQ:RYOJ) which gained 140.00% to close at 9.12.

The worst performers were Neuphoria Therapeutics Inc (NASDAQ:NEUP) which was down 68.51% to 4.85 in late trade, American Rebel Holdings Inc (NASDAQ:AREB) which lost 33.16% to settle at 1.25 and SMX Security Matters Ord Shs Class A (NASDAQ:SMX) which was down 32.75% to 0.78 at the close.

Rising stocks outnumbered declining ones on the New York Stock Exchange by 1496 to 1268 and 76 ended unchanged; on the Nasdaq Stock Exchange, 1771 fell and 1612 advanced, while 156 ended unchanged.

Shares in General Motors Company (NYSE:GM) rose to all time highs; gaining 14.82% or 8.60 to 66.60. Shares in Warner Bros Discovery Inc (NASDAQ:WBD) rose to 3-years highs; rising 10.97% or 2.01 to 20.33. Shares in 3M Company (NYSE:MMM) rose to 3-years highs; up 7.66% or 11.86 to 166.64. Shares in Minerva Neurosciences Inc (NASDAQ:NERV) rose to 52-week highs; rising 140.98% or 3.75 to 6.41. Shares in American Rebel Holdings Inc (NASDAQ:AREB) fell to all time lows; falling 33.16% or 0.62 to 1.25. Shares in rYojbaba Co Ltd (NASDAQ:RYOJ) rose to all time highs; gaining 140.00% or 5.32 to 9.12. Shares in SMX Security Matters Ord Shs Class A (NASDAQ:SMX) fell to all time lows; down 32.75% or 0.38 to 0.78.

The CBOE Volatility Index, which measures the implied volatility of S&P 500 options, was down 1.97% to 17.87.

Gold Futures for December delivery was down 5.14% or 223.96 to $4,135.44 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in December rose 1.00% or 0.57 to hit $57.59 a barrel, while the December Brent oil contract rose 1.03% or 0.63 to trade at $61.64 a barrel.

EUR/USD was unchanged 0.35% to 1.16, while USD/JPY rose 0.78% to 151.93.

The US Dollar Index Futures was up 0.40% at 98.75.

Investing.com -- Minerva Neurosciences (NASDAQ:NERV) stock soared 130% after the company announced it has secured up to $200 million in financing to advance its schizophrenia treatment candidate through a confirmatory Phase 3 trial.

The clinical-stage biopharmaceutical company said it entered into a securities purchase agreement with institutional investors that will provide $80 million in upfront funding and up to an additional $80 million if all Tranche A warrants are exercised. A further $40 million may be received if Tranche B warrants are exercised upon achievement of a milestone event.

The financing follows Minerva’s August announcement that it had aligned with the FDA on the design of a confirmatory Phase 3 trial for roluperidone, its treatment for negative symptoms in patients with schizophrenia. The company expects the proceeds will fund the trial, NDA resubmission, and potential commercial launch preparations.

"We will now refocus all of our efforts on the successful execution of the confirmatory trial with the objective of demonstrating that roluperidone can effectively treat patients with impairing negative symptoms," said Dr. Remy Luthringer, Chairman and CEO of Minerva.

The private placement, led by Vivo Capital LLC with participation from investors including Janus Henderson and Federated Hermes Kaufmann Funds, is expected to close around October 23, 2025.

As part of the agreement, Minerva will appoint up to three new directors with significant schizophrenia clinical trial experience to strengthen its clinical operations team. The company will also establish a Scientific Advisory Board to provide oversight for the confirmatory trial.

The Phase 3 trial will evaluate a 64 mg dose of roluperidone in a 1:1 randomized double-blind, placebo-controlled study, with the primary endpoint being the change in PANSS Marder negative symptoms factor score at 12 weeks compared to placebo.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.